Lung Cancer ALI Organoids Retain a Short Window for Immune and Radiation Tests
A cell-based air–liquid interface culture retained endogenous immune cells more effectively than dome culture, although immune content declined with passage. Small model subsets tested pembrolizumab, radiation and a radiation–STING-agonist combination without validating clinical checkpoint-response prediction.
Improving Formation While Keeping Native Immune Cells
Lung cancer organoids often lose the immune cells present in the original tissue. Researchers from Hangzhou Cancer Hospital and collaborating academic centers compared culture formats intended to preserve those cells while supporting epithelial growth. Their Cellular Oncology study used a cell-based air–liquid interface, or ALI, approach to examine checkpoint blockade and radiation responses within a short culture window.
The ALI system established organoids from 16 of 19 patient samples, an 84% formation rate. A direct comparison between cell-based and minced-tissue ALI methods used four patients. One sample failed with the tissue method but formed organoids with the cell method; the other three yielded more organoids with the cell method. Immune-cell comparisons between matched formats used three patient samples.
These paired comparisons support the culture change more directly than comparisons with previously published establishment rates. The investigators also compared ALI cultures with conventional matrix domes, assessing epithelial growth alongside fibroblast and endogenous immune-cell retention.
Retention Was Better, but Declined During Culture
Adding interleukin-2 to dome cultures increased immune-cell fractions in three of four primary models, without a significant overall difference. Growth after passage was impaired, and subsequent organoids failed to form. The intervention therefore did not provide a durable solution to maintaining both the tumor and its immune population.
Immune fractions fell with passage in both formats. ALI cultures retained roughly 25% immune cells after passage in the reported comparison, while dome cultures approached zero. The authors favored testing within the first passage, when the starting immune environment was better represented.
Single-cell analysis at day 15 compared parental tumor, ALI and dome cultures with or without interleukin-2. It resolved seven major cell types and six T-cell subtypes. The cultures preserved parts of the original immune landscape but underrepresented exhausted CD8 cells and monocytes, while stress and MHC class II-associated programs changed. The retained population therefore differed from the source tumor in both composition and state.
Checkpoint Responses Varied Across Five Models
Five models received pembrolizumab at 10 μg/mL or an IgG4 control for seven days. Two showed a response. In one responsive model, granzyme B increased without a corresponding increase in interferon-γ, illustrating that immune readouts did not move uniformly.
The study compared the proportion of responding cultures with published population response rates, but did not match organoid checkpoint responses to the corresponding patients’ clinical immunotherapy outcomes. The two-of-five result establishes activity in a small experimental subset, with individual clinical prediction still untested.
Radiation and STING Stimulation Supplied a Second Treatment Question
Radiation experiments tested 0, 4, 8 and 16 Gy and followed organoid area through day 24. A paired clinical radiation example supplied a case-level comparison. Organoid area captured structural response, while the accompanying immune and expression measurements addressed additional parts of the treatment effect.
Four models were used to compare radiation, the STING agonist diABZI and their combination. DiABZI was applied at 5 μM for two hours daily over four days after irradiation. The combination produced greater organoid collapse than the individual treatments, together with increases in IFIT1, IFIT2 and IFNB1 expression. This is preclinical combination evidence; it does not establish a lower effective radiation dose for patients.
Culture Timing Determines What the Assay Can Represent
The study connects a practical culture comparison to two immune-related treatment questions. Cell-based ALI supported more frequent organoid formation in the paired comparison and preserved endogenous immune cells longer than domes. Declining immune abundance, altered cell states and different patient subsets for each analysis remain central to interpreting the assays. Broader paired clinical studies would be needed to test prediction, while treatment experiments in this system should account for the short interval in which its native immune component remains representative.